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Purpose: The goal of this study was to determine the role of the neonatal Fc (FcRn) receptor in eliminating intravitreally
administered full-length immunoglobulin G (IgG) across the blood-retinal barrier.
Methods: FcRn receptor expression in normal and laser photocoagulated retinas was compared quantitatively by real-
time RT–PCR. The distribution of intravitreally administered full-length IgG was investigated and compared in wild-type
and FcRn knockout mouse eyes as well as normal and laser-photocoagulated rat eyes at several time points. Additionally,
the pharmacokinetics of intravitreally injected full-length IgG and chicken immunoglobulin Y (IgY) was compared in the
normal rat retina.
Results: Intravitreally administered full-length IgG overcame the inner limiting membrane and diffused into the deeper
retinal structures in both normal and laser-photocoagulated retinas. Interestingly, IgG was eliminated across the blood-
retinal barrier into the blood system in the normal retina, whereas IgY was not. In addition, full-length IgGs did not
penetrate across the blood-retinal barrier in the FcRn knockout mouse. Intravitreally injected IgGs were eliminated into
the blood system more rapidly in laser-photocoagulated eyes when compared to normal control eyes because of FcRn
receptor upregulation in the laser-photocoagulated retina.
Conclusions: FcRn plays an important role in eliminating intravitreally administered full-length IgGs across the blood-
retina barrier into the systemic blood system.
Interest in antibody-based treatment for retinal disorders
has recently increased with the availability of efficacious and
FDA-approved antibodies. To date, more than 20 antibodies
have been approved by the United States Food and Drug
Administration (FDA) for therapeutic use in humans [1]. At
least five humanized monoclonal antibodies are being tested
in more than ten ocular clinical trials (March 2009). Direct
intravitreal  injection  has  become  a  common  approach  for
delivering therapeutic antibodies to the posterior segment of
the eye for retina disorders. Although intravitreally injected
full-length antibodies penetrate the retina as easily as antibody
fragments [2], the fate of these antibodies after they access the
retina is not yet understood.
The inner blood-retinal barrier plays an important role in
supplying oxygen and nutrients to the retinal cells, not unlike
that performed by the blood-brain barrier [3]. It is formed by
complex tight junctions on the retinal capillary endothelial
cell, which are themselves further enveloped with pericytes
and  Müller  cells  [3].  Thus,  the  blood-retinal  barrier  is
structurally  similar  to  the  blood-brain  barrier  [4].  Several
influx  and  efflux  transporters  have  been  identified  and
characterized  in  brain  capillary  endothelial  cells  [3,5].
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Schlachetzki et al. [6] determined that the blood-brain barrier
contains the neonatal Fc (FcRn) immunoglobulin G (IgG)
receptor/transporter [6]. Efflux of intracerebral IgG is FcRn-
mediated as intracerebral IgG elimination into the systemic
circulation is competitively inhibited by Fc fragments, which
block the FcRn receptor, but not impeded by Fab fragments,
which do not bind to the FcRn receptor [7,8]. In addition,
Deane et al. [9] concluded that the FcRn pathway at the blood-
brain barrier plays a crucial role in IgG-associated amyloid
beta peptide removal from the aging brain [9]. In prior studies,
we have established the expression of FcRn at the blood-
retinal barrier [10]. Therefore, in this study, we investigated
the trans-retinal penetration and FcRn-dependent elimination
of intravitreally administered IgG across the blood-retinal
barrier.
METHODS
Animals: Male adult (250 g) Brown Norway rats (Charles
River Laboratories, Raleigh, NC) was used in the study. All
the animals were housed under a 12 h light-dark cycle with
standard  diet  and  free  access  to  water  ad  libitium.  All
procedures adhered to the guidelines from the Association for
Research  in  Vision  and  Ophthalmology  for  the  Use  of
Animals in Research.
Intravitreal injection of fluorescence labeled antibody in rats:
Two  ml  of  Alexa  555  conjugated  goat  anti-rabbit  IgG
(GAR555; H+L; Invitrogen, Carlsbad, CA) were dialyzed two
times overnight with a dialysis cassette (MWCO=10 kDa;
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2803Pierce, Rockford, IL) in 1,000 ml of 1× phosphate-buffered
saline (PBS, 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4,
1.8 mM KH2PO4, pH 7.4) to facilitate removal of dissolved
sodium azide. And then, the dialyzed antibody solution was
centrifugated  at  16,873×  g  for  5  min  at  4  °C  to  remove
antibody aggregate. Rats aged 8–12 weeks were anesthetized
by intramuscular injection of 70 mg/kg ketamine and 30 mg/
kg  xylazine  before  both  pupils  were  dilated  with  10%
tropicamide (Mydriacyl; Alcon, Fort Worth, TX). Next, 5 μl
of  the  aforementioned  antibody  solution  (2  mg/ml)  was
injected  intravitreally  into  the  right  eye  with  a  32-gauge
needle. After CO2 euthanasia, the injected eyes were then
enucleated  at  either  30  min,  6  h,  or  15  h  post  injection,
respectively.  The  enucleated  eyes  were  immediately
immersed in a 4% paraformaldehyde (PFA) solution and held
at 4 °C overnight. The fixed eyes were then placed in 1× PBS
at  4  °C  until  the  next  experiments.  To  determine  the
distribution  of  intravitreally  injected  antibody  in  a  post-
mortem eye, we immediately injected 5 μl of GAR555 (2 mg/
ml) after CO2 euthanasia. The eye was enucleated, kept in 1×
PBS for 6 h at 4 °C and then fixed overnight with 4% PFA
solution at 4 °C. As described, the eyes were stored in 1× PBS
at 4 °C until the next steps.
Retinal laser photocoagulation model in rats: To determine
the distribution of intravitreally injected antibody in a laser
photocoagulated retina, we created a laser-photocoagulated
retina.  Animals  were  anesthetized  as  described  in  the
preceeding paragraph. The right eye was dilated with 1%
tropicamide.  Hydroxypropyl  methylcellulose  (DECA
Pharmaceuticals, LLC, Bowling Green, KY) was applied to
each eye, and a microscope slide cover glass was used as a
contact lens. The right eyes each received nine laser burns
(3×3 grid pattern) between retinal vessels using the blue-green
setting of a Lumenis Ultima Argon Laser (Lumenis Inc., New
York, NY). The laser power was 180 mW for 0.1 s with a
50 µm spot diameter. The retina was examined to confirm no
bleeding had occurred. Two weeks later, 5 µl of GAR555
(2 mg/ml) was injected as described. The eyes were then
enucleated at either 1 h or 3 h post injection before immediate
fixation in 4% PFA solution at 4 °C overnight. The fixed eyes
were stored in 1× PBS at 4 °C until the next experiments. The
optic nerve and conjunctival tissues above the sclera were
carefully  removed  and  the  fixed  eye  was  opened  by  a
circumferential incision at the surgical limbus. The anterior
segment and lens were removed, and the retina was gently
separated from the sclera tissue. The retina was embedded in
7% agarose type XI gel (Sigma, St. Louis, MO) and sectioned
into 100 µm-thick slices with a vibrating blade microtome
(Leica, Bannockburn, IL). The eye sections were incubated
overnight in 1:1,000 DAPI solution diluted with ICC buffer
(PBS containing 0.5% BSA, 0.2% Triton X-100, and 0.05%
sodium azide, pH 7.4) and then washed for 3 h three times
with ICC buffer. Finally, the eye sections were embedded in
mounting medium (Vectashield, Vector Laboratories, Inc.,
Burlingame, CA) and sealed under microscope cover glass
slides before being viewed on a Leica laser scanning confocal
microscope.
Expression of FcRn receptor in the laser-photocoagulated
retina of rats: The FcRn mRNA level in laser photocoagulated
retinas was compared with that in normal retinas using the
following technique. Animals received 20 laser burns in each
eye. Retinal tissue (each group n=4) was carefully isolated
from the enucleated eyes immediately after CO2 euthanasia.
Total RNA was then isolated and purified from the retinal
tissue with the TRIzol plus RNA purification kit (Invitrogen)
according  to  the  manufacturer’s  protocol.  The  first-strand
cDNA  was  synthesized  from  2  µg  of  total  RNA  with
SuperScript  III  first-strand  synthesis  system  for  RT–PCR
(Invitrogen)  following  the  manufacturer’s  protocol.  The
resulting first-strand cDNAs were stored at −80 °C before use.
Aliquots of cDNA were subjected to PCR reaction using the
following custom-made amplification [11] primers 5′- CTG
TGG ATG AAG CAA CCT G-3′ and 5′-TCC ACG TTT GAC
CTC TAG C-3′ (Integrated DNA Technologies, Coralville,
IA).
Distribution  of  intravitreally  injected  bevacizumab  in  the
FcRn  knockout  and  wild-type  mice:  We  injected  1  µl
bevacizumab  (25  mg/ml)  intravitreally  in  FcRn  knockout
mice  (B6.129X1-Fcgrttm1Dcr/Dcr)  and  wild-type  mice
(C57BL/6J) were purchased from Jackson Laboratory (Bar
Harbor, ME). All mice were housed at specific pathogen-free
facilities. Water and food were provided ad libitum. The eyes
were enucleated 5 h post injection and fixed immediately with
4%  PFA  solution.  The  fixed  eye  was  opened  by  a
circumferential  incision  at  the  surgical  limbus.  After  the
anterior segment of the eye and lens was removed, the retina
was carefully separated from the sclera tissue. The retina was
embedded in 7% agarose type XI gel (Sigma) and sectioned
into 100 μm-thick slices with a vibrating blade microtome
(Leica). The bevacizumab (recombinant humanized IgG1) in
the retina was determined with Alexa 488 conjugated goat
anti-human  IgG.  The  isolated  retinas  were  incubated
overnight in 1:1,000 DAPI and 1:200 Alexa 488 conjugated
goat anti-human IgG diluted with ICC buffer. Retinas were
then washed for 3 h three times with ICC buffer. The eye
sections were embedded in mounting medium (Vectashield)
and  sealed  under  microscope  cover  glass  slides.  The  eye
sections were viewed on a laser scanning confocal microscope
and the fluorescence intensities across the retinal capillaries
were  determined  with  Image  J  (version  1.49  g;  National
Institutes  of  Health,  Bethesda,  MD).  Finally,  these
fluorescence  intensity  values  were  normalized  using  the
maximum intensity value at the abluminal side of the retinal
capillary as the normalizing value.
Pharmacokinetics of intravitreally injected bevacizumab in
the laser photocoagulated eye of rats: Two weeks after the
rats were given their laser burns, both lasered and non-lasered
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same anesthesia technique described in the previous section.
Additionally, left eye analgesia and pupillary dilation were
achieved with 1 drop of 0.5% proparacaine hydrochloride
(Alcon,  Barrio  Palmas,  Puerto  Rico)  and  1  drop  of  2.5%
phenylephrine  hydrochloride  (Akron,  Inc.,  Decatur,  IL),
respectively.  The  left  eye  was  then  examined  using
methylcellulose and a microscope slide coverslip to confirm
CNV within the retina of the laser photocoagulated animals.
In both the laser photocoagulated and non-lasered control
groups, the left retina was subsequently injected intravitreally
roughly  1  mm  behind  the  surgical  limbus  in  the
superotemporal quadrant with 2 µl bevacizumab at 25 mg/ml
(50 μg) using a 30-gauge syringe (Hamilton, Reno, NV). Five
hours later, blood samples were obtained intracardially from
the animals and then the animals were euthanized with CO2.
Serum samples were immediately collected from the blood
samples.
Bevacizumab  enzyme-linked  immunosorbent  assay:
Bevacizumab  concentrations  in  serum  samples  were
quantified by enzyme-linked immunosorbent assay (ELISA).
All  steps  were  performed  at  room  temperature.  A
Microlite2+high-binding  96-well  plate  (Thermo  Fisher
Scientific, Waltham, MA) was coated with goat anti-human
IgG  affinity  purified  antibody  (Bethyl  Laboratories,
Montgomery, TX) diluted to 10 µg/ml in coating buffer (0.05
M carbonate-bicarbonate, pH 9.6). After 1 h incubation, each
well was washed three times with 200 µl of washing solution,
which  contained  50  mM  Tris,  0.14  M  NaCl,  and  0.05%
Tween-20, pH 8.0. Samples were then blocked for 30 min with
200 µl of blocking solution, which contained 50 mM Tris, 0.14
M NaCl, and 1% BSA, pH 8.0. Each well was then washed
three times with 200 µl of washing solution.
Samples were diluted 1:100 in sample diluent, which
contained 50 mM Tris, 0.14 M NaCl, 1% BSA, and 0.05%
Tween-20, pH 8.0. Approximately 100 µl of diluted sample
were aliquoted into each well, and samples were incubated for
1 h. After the incubation, each well was washed five times
with 200 µl of washing solution. Next, 100 µl of biotin-labeled
Fc  fragment  specific  goat  anti-human  IgG  with  minimal
reactivity to Mouse IgG (eBioScience, San Diego, CA) was
diluted  to  20  µg/ml  in  the  previously  described  sample
diluents and added to each well and samples were incubated
for  1  h  before  being  washed  with  the  washing  solution.
Afterwards,  100  µl  of  Alexa  Fluor  488  conjugated
streptavidin, which had been diluted to 10 µg/ml in the sample
diluents was added to each well, and samples were incubated
for  1  h  before  being  washed  with  the  washing  solution.
Finally, after 100 µl of PBS was added to each well, the plate
was read at an excitation of 485 nm and emission of 525 nm.
The  standard  curve  was  obtained  by  serial  dilutions  of  a
25  mg/ml  bevacizumab  solution  (Genentech  Inc.,  San
Francisco,  CA).  The  bevacizumab  concentration  in  each
diluted serum sample was determined from the standard curve
using linear regression. The bevacizumab concentration of
these diluted samples was then used to calculate the original,
undiluted bevacizumab concentration in the serum.
Pharmacokinetics of intravitreally injected bevacizumab and
chicken IgY in rats: Rats were given intravitreal injections of
2 µl of either 5.7 mg/ml bevacizumab or 5.7 mg/ml chicken
IgY  (Jackson  ImmunoResearch  Laboratories,  Inc.,  West
Grove, PA). Then 5 h post injection, the eyes were enucleated
after CO2 euthanasia and immediately fixed in 4% PFA. Next,
10 μm-thick frozen sections of either bevacizumab- or chicken
IgY-injected  eyes  were  prepared  as  described.  The
distribution  of  either  bevacizumab  or  chicken  IgY  in  the
frozen sections was determined with Alexa dye conjugated
goat  anti-human  IgG  or  Alexa  dye  conjugated  goat  anti-
chicken IgG, respectively.
RESULTS
Intravitreally administered full-length antibody distribution
in  the  rat  retina:  Intravitreally  administered  full-length
antibody overcame the inner limiting membrane barrier and
diffused  into  the  deeper  retinal  structures  in  both  laser-
photocoagulated and non-lasered rat retinas (Figure 1A-C).
The  antibody  did  not  penetrate  the  external  limiting
membrane  but,  instead,  actually  accumulated  along  the
external limiting membrane in non-lasered retinas (Figure
1C). On the other hand, the antibody easily penetrated the
retina into the subretinal layer and Bruch’s membrane region
in  laser  photocoagulated  retinas  (Figure  1D-E).  Figure  1
demonstrates the prevalence of IgG associated with the retinal
capillaries in both normal and laser-photocoagulated retinas.
Figure  2A,B  demonstrate  injection  of  full-length  IgG
antibody intravitreally to a live eye and a postmortem eye to
see the different distribution of the injected antibody in the
live and postmortem retinas, respectively. More antibodies
were observed in the postmortem retina, compared to the live
one,  which  strongly  suggests  the  presence  of  active
elimination mechanisms for IgG in the live retina.
The  pharmacokinetics  of  intravitreally  injected  full-length
IgGs in the laser-photocoagulated rat eye: Real-time RT–
PCR study demonstrated a 1.82-fold upregulation of the FcRn
receptor  in  laser-photocoagulated  retinas,  relative  to  non-
lasered age-matched control retinas (p<0.05) (Figure 3A).
Moreover, the serum concentration of bevacizumab 5 h post
intravitreal injection was 279 ng/ml in the control group and
832  ng/ml  in  laser-photocoagulated  group,  respectively
(p<0.05; Figure 3B). Accordingly, laser photocoagulation of
the retina upregulated FcRn expression and resulted in a more
rapid  elimination  of  IgG  from  the  eye  into  the  systemic
circulation.
Intravitreally  administered  full-length  IgG  distribution  in
FcRn knockout and wild-type mouse eyes: Figure 4 shows and
compares  the  distribution  of  intravitreally  administered
bevacizumab, a full-length IgG, around retinal blood vessels
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2805in an FcRn knockout mouse and wild-type mouse 5 h post-
injection. Interestingly, bevacizumab was only observed at the
abluminal side of retinal blood vessels in the FcRn knockout
mouse (Figure 4A). However, bevacizumab was detected not
only abluminally but also within the lumen of the retinal blood
vessels in wild-type mouse retina (Figure 4B). Moreover, it
was even detected inside the vascular endothelial cells of wild-
type  mouse  retinal  blood  vessels.  Figure  4C  shows  the
normalized fluorescence intensity profile gradient across the
retinal  endothelium,  demonstrating  the  penetration  of
bevacizumab through the retinal vascular endothelium into
the blood system in the wild-type mouse.
Pharmacokinetics  of  intravitreally  injected  bevacizumab
(IgG) and chicken IgY in the rat eye: Figure 5 compares the
retinal  distribution  of  IgG  and  chicken  IgY,  which  is
structurally similar to IgG but does not bind to the FcRn
receptor [12]. Both intravitreally administered bevacizumab
(IgG) and chicken IgY overcame the inner limiting membrane
barrier and diffused into the deeper retinal structures (Figure
5A,D). Figure 5E demonstrates that after diffusing through
the retina bevacizumab crossed the blood-retina barrier and
leaked  into  the  systemic  circulation,  thus  explaining  why
bevacizumab is observed within the choroidal vasculature in
Figure 5F. The intraretinal chicken IgY was only localized
along the abluminal side of the blood-retina barrier (Figure
5B). Furthermore, the choroidal blood vessels were negative
for the presence of chicken IgY (Figure 5C).
DISCUSSION
Several  previous  studies  have  reported  that  trans-retinal
penetration varies with the molecular weight of the diffusing
agent  [13-16].  An  in  vitro  study  suggested  the  maximum
molecular size capable of freely diffusing across the human
retina  was  approximately  76.5  kDa  [17].  One  possible
explanation for why our in vivo data (Figure 1) differs from
previous  in  vitro  studies  may  be  the  resultant  structural
changes in retinal integrity that inevitably occur with tissue
Figure 1. The distribution in rat eyes of intravitreally administered fluorescent dye labeled full-length IgG (red). A-C show the distribution
of the full-length IgG in the normal retina at 30 min, 6 h, and 15 h post intravitreal administration, respectively. D and E show the distribution
of the full-length IgG in the laser-photocoagulated retina at 1 h and 3 h post intravitreal administration, respectively. Intravitreally administered
full-length antibody overcame the inner limiting membrane barrier and diffused into the deeper retinal structures in both laser photocoagulated
and control rat retinas. A–E: Cell nuclei were stained with DAPI (blue). Abbreviations: inner limiting membrane (ILM), ganglion cell layer
(GCL), inner plexiform layer (IPL), inner nuclear layer (INL), outer plexiform layer (OPL), outer nuclear layer (ONL), external limiting
membrane (ELM), and Bruch’s membrane (BM).
Molecular Vision 2009; 15:2803-2812 <http://www.molvis.org/molvis/v15/a296> © 2009 Molecular Vision
2806fixation. Fixation involves cross-linkage of amino groups,
causing a shrinkage of tissues and ultimately an alteration in
the  diffusion  channels  within  these  tissues.  Furthermore,
active transport mechanisms present in vivo are not present in
fixed in vitro tissues. Therefore, in vitro results may be of
limited utility for explaining in vivo experimental data, much
less predicting clinical pharmacological phenomena observed
in patients.
Figure  1A-C  demonstrates  that  the  inner  limiting
membrane provided a limited degree of resistance against the
penetration of full-length antibody at early time points. The
inner  limiting  membrane  is  composed  of  a  fine  three-
dimensional meshwork structure, the pore diameter of which
varies between 10 and 25 nm [18]. Stokes radius of full-length
IgG is around 5.5 nm [19]. Accordingly, a 5.5-nm full-length
antibody could diffuse through the inner limiting membrane
into the deeper retinal structures with time. Although the inner
limiting membrane acts as a filter between the retina and
vitreous cavity, it is a poor barrier against the penetration of
intravitreal full-length IgG into the retina.
Figure  1C  shows  that  intra-retinal  full-length  IgG
accumulated along the external limiting membrane in normal
retinas. The external limiting membrane is composed of a row
of zonulae adherents with a pore radius between 3.0 and 3.6
nm  that  effectively  joins  photoreceptors  and  Müller  cells
[14,20]. This physically smaller pore size compared to the
Stokes  radius  of  full-length  IgG  explains  the  absence  of
bevacizumab within the retinal pigment epithelium (RPE) and
photoreceptor  cell  layer  in  a  normal  retina  following
intravitreal  injection.  Conversely,  laser  photocoagulation
disrupts the external limiting membrane and extends the outer
nuclear layer into Bruch’s membrane and the choroid [21,
22]. So, the intravitreal administration is able to deliver full-
length  antibody  into  the  subretinal  space  and  Bruch’s
membrane region because of the resultant changes in retinal
morphology that occur with CNV. This explains the clinical
utility of intravitreal bevacizumab against age-related macular
degeneration-associated choroidal neovascularization.
The predominant elimination pathways for compounds
leaving the vitreous are either into the anterior segment or
across the retina. Moreover, prevailing dogma regarding the
elimination route of intravitreal compounds suggests that the
relative  contribution  of  each  route  depends  solely  on  the
physicochemical  properties  of  a  given  compound  (e.g.,
lipophilicity  and  molecular  size).  For  example,  lipophilic
compounds such as triamcinolone appear to be eliminated
predominantly  across  the  retina,  while  large,  hydrophilic
compounds primarily diffuse into the aqueous humor before
being  eliminated  through  conventional  aqueous  humor
outflow  pathways  with  the  anterior  chamber  (trabecular
meshwork  and  Schlemm’s  canal)  [23,24].  However,  are
physicochemical  properties  alone  enough  to  explain  the
pharmacokinetics of intravitreally administered compounds?
The physicochemical properties of fluorescein (MW=376 Da,
Figure 2. The distribution in rat eyes of intravitreally administered fluorescent dye labeled full-length IgG (red). A and B show the distribution
of the full-length IgG in the live and post-mortem retina 6 h post intravitreal administration, respectively. More antibodies were observed in
the post-mortem retina, compared to the live retina, suggesting the presence of active elimination mechanisms for IgG in the live retina. A,
B: Cell nuclei were stained with DAPI (blue). Abbreviations: inner limiting membrane (ILM), ganglion cell layer (GCL), inner plexiform
layer (IPL), inner nuclear layer (INL), outer plexiform layer (OPL), outer nuclear layer (ONL), and external limiting membrane (ELM).
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2807hydrophilic)  and  fluorescein  glucuronide  (MW=508  Da,
hydrophilic) are similar. The diffusion coefficients of these
compounds  in  the  aqueous  phase  are  essentially  equal
(6×10−6 cm2s−1) [25]. Nevertheless, it is well known that the
pharmacokinetics of fluorescein and fluorescein glucuronide
in  the  vitreous  are  actually  quite  different.  Fluorescein  is
eliminated across the retina while fluorescein glucuronide is
eliminated into the anterior segment [26]. The starkly different
elimination  patterns  of  these  two  compounds  cannot  be
explained solely on physicochemical properties. Instead, one
must  also  account  for  the  differential  effect  of  biologic
relevant  transport  mechanisms.  Vitreal  clearance  of
fluorescein  glucuronide  is  largely  governed  by  passive
diffusion,  while,  the  vitreal  elimination  of  fluorescein  is
largely dependent on active transport [27]. As documented in
the  literature  [2],  the  current  study  confirmed  that
intravitreally administered bevacizumab is able to easily and
rapidly penetrate the retina before being eliminated into the
blood  circulation  across  the  inner  blood  retina  barrier.
Additionally, intravitreal antibody is eliminated both across
the  iris  vascular  endothelial  and  ciliary  body  nonpigment
epithelial tight junctions into the blood system and through
conventional aqueous humor outflow pathways [28]. Finally,
we  documented  physiologically  relevant  serum  levels  of
bevacizumab after intravitreal administration, representing up
to 30% of the injected dose. Of concern, this suggests greater
risk  for  systemic  side  effects  than  previously  recognized
[29]. Of note, in the rabbit five-day half-life of bevacizumab
Figure  3.  Correlation  between  the
expression  of  FcRn  receptor  and  the
serum  concentration  of  intravitreally
administered  bevacizumab.  A:  Real-
time  RT–PCR  study  in  rats
demonstrated a 1.82-fold upregulation
of  FcRn  mRNA  expression  in  laser-
photocoagulated  retinas,  relative  to
normal retinas (n=5, p=0.001). B: The
serum concentration of bevacizumab in
the  laser-photocoagulated  group  (832
ng/ml)  was  higher  than  that  in  the
control  group  (279  ng/ml)  5  h  post
intravitreal  administration  of  2  µl
bevacizumab  at  25  mg/ml  (n=4;
p<0.05).  The  error  bars  are  standard
error of the mean.
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2808Figure 4. Distribution of intravitreally injected bevacizumab in the FcRn knockout and wild-type mice. A and B show the distribution of
intravitreally administered bevacizumab (green) around retinal blood vessels in an FcRn knockout mouse and wild-type mouse 5 h post
injection, respectively. C shows the normalized fluorescent intensity across the retinal vascular endothelium in a wild-type mouse. Arrows in
B indicate the direction over which the fluorescence profiles were obtained. The normalized fluorescence intensity profile in panel C shows
a fluorescence intensity gradient across the retinal vascular endothelium from the abluminal to luminal sides, indicating the penetration of
bevacizumab into the blood system in the wild-type mouse. A, B: Cell nuclei were stained with DAPI (blue).
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half-life of ranibizumab (the Fab fragment of bevacizumab),
which is much less than would be expected for a molecule
threefold larger than ranibizumab [30-32]. Taken together, the
data indicate the blood-ocular barrier manifests a specific
mechanism for transporting and clearing full-length IgGs into
the  systemic  circulation.  The  current  study  confirms  our
hypothesis that this mechanism is the neonatal Fc receptor.
Anti-vascular  endothelial  growth  factor  (VEGF)
antibodies, such as bevacizumab, are the first-line treatment
for  choroidal  neovascularization  in  age-related  macular
degeneration patients. Accordingly, it is imperative from a
clinical standpoint for the intraocular pharmacokinetics of
full-length  IgG  to  be  established.  If  choroidal
neovascularization  significantly  alters  the  vitreous
elimination of IgG, the frequency with which patients receive
intraocular IgG injections should be tailored to the level of
choroidal neovascularization–just as patients with hepatic or
renal dysfunction are dosed based upon their level of organ
impairment. This is a novel and, as yet, unexplored area of
ophthalmology. In this study, we evaluated whether animals
exhibiting  choroidal  neovascularization  had  increased
clearance  of  full-length  IgG  from  the  eye.  Figure  3
demonstrates  both  upregulation  of  the  FcRn  receptor  and
faster elimination of intravitreally injected bevacizumab into
the systemic circulation in the choroidal neovascularization
animal model with respect to age-matched control animals
without choroidal neovascularization. The pathogenesis of
choroidal  neovascularization  is  complex,  involving  RPE
alterations,  Bruch’s  membrane  rupture,  angiogenesis,  and
vasculogenesis–all of which are all strongly influenced by
inflammatory mediators [33]. While it is well described that
VEGF  triggers  many  of  the  vascular  changes  underlying
choroidal neovascularization, new evidence suggests tumor
necrosis factor α (TNF-α) is not only increased in the laser
photocoagulation choroidal neovascularization model (4–5
fold) but actually contributes to the development of choroidal
neovascularization  [33,34].  Injection  of  either  etanercept
(soluble  TNF-α  receptor)  or  a  monoclonal  anti-TNF-α
antibody (infliximab), each of which decrease effective levels
of  TNF-α,  reduce  the  size  and  leakage  of  laser-induced
choroidal neovascularization. Moreover, TNF-α upregulates
Figure 5. Pharmacokinetics of intravitreally injected bevacizumab and chicken IgY in rats. A–C show the distribution in rat eyes of chicken
IgY in the whole retina (A), around the retinal blood vessel (B), and in the choroid (C) 5 h post intravitreal injection as determined by Alexa
dye labeled antibodies (red). D–F show the distribution in rat eyes of bevacizumab in the whole retina (D), around the retinal blood vessel
(E), and in the choroid (F) 5 h post intravitreal injection as determined by Alexa dye labeled antibodies (red).
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2810both  FcRn  expression  and  function,  as  demonstrated  by
increased IgG transport across an epithelial monolayer with
TNF-α stimulation [35]. Accordingly, merging these two lines
of evidence, namely that TNF-α is increased in laser choroidal
neovascularization  and  TNF-α  enhances  FcRn  expression,
may  explain  why  the  laser  choroidal  neovascularization
model has increased FcRn function (Figure 3A). This would
translate  into  more  rapid  elimination  of  intravitreally
administered IgG into the blood system, which is exactly what
we  observed  in  laser  CNV  model  rats  (Figure  3B).  The
inhibition  of  FcRn  upregulation  or  the  FcRn  elimination
pathway itself may mitigate this increased elimination and
thereby enhance the intravitreal half-life of IgG. A method to
decrease elimination of IgG from the eye provides a future
direction for extending the results of this current study and
potentially  decreasing  the  frequency  of  intraocular  IgG
injection.
In conclusion, the human blood-ocular barrier expresses
the FcRn receptor. In addition, FcRn plays an important role
in  eliminating  intravitreally  administered  full-length  IgGs
across the blood-retina barrier into the systemic blood system.
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